Pfizer’s Sasanlimab Shows 32% Reduced Risk of Disease Events in Bladder Cancer Trial
Pfizer has announced the results from a phase 3 bladder cancer trial, showing that its PD-1 inhibitor sasanlimab reduced the risk of disease-related events by 32%. However, the study did not demonstrate overall survival benefits and saw an increased rate of serious adverse events in the treatment arm. The trial found patients who received sasanlimab … Read more